Showing results (81-90 of 209) with videos related to

Sort By:
Pageof 21
Cytotherapy|May 21, 2014
T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1Simone Krebs, Kevin K H Chow, Zhongzhen Yi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 5, 2017
Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck CancerAmanda Rosewell Shaw, Caroline E Porter, Norihiro Watanabe, et al.
Journal of Pediatric Hematology/Oncology|July 5, 2007
A single institution experience with pediatric nasopharyngeal carcinoma: high incidence of toxicity associated with platinum-based chemotherapy plus IMRTChrystal U Louis, Arnold C Paulino, Stephen Gottschalk, et al.
Blood|November 13, 2004
Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytesEttore Biagi, Gianpietro Dotti, Eric Yvon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 14, 2020
Toward Functional Immune Monitoring in Allogeneic Stem Cell Transplant RecipientsSwati Naik, Spyridoula Vasileiou, Paibel Aguayo-Hiraldo, et al.
Molecular Therapy Oncolytics|September 1, 2017
T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCCArpad Szoor, Abishek Vaidya, Mireya Paulina Velasquez, et al.
Blood|November 2, 2002
Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignanciesStephen Gottschalk, Oliver L Edwards, Uluhan Sili, et al.
Research Square|February 27, 2026
Antigen Specificity and Cell Engineering Determine CAR T Cell Efficacy in Group 3 MedulloblastomaGiedre Krenciute, Meghan Ward, Justine Fouliard, et al.
Cancer Cell|July 14, 2021
The role of exhaustion in CAR T cell therapyGreg M Delgoffe, Chenqi Xu, Crystal L Mackall, et al.
Cytotherapy|November 7, 2018
Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapyMamta Kalra, Ulrike Gerdemann, Jessica D Luu, et al.
Pageof 21